Clinical trial
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
NCT03805100 is registered in ClinicalTrials.gov with Xbrane Biopharma AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
- Lead sponsor
- Xbrane Biopharma AB
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 19, 2019
- Completion date
- November 11, 2021
- Enrollment
- 582 (actual)
- Sites
- 102
Conditions
As the registry lists them; a condition with its own page is linked.